Get the Stockscreener App
22.42
3.70%
0.80
After Hours:
22.42
Arrivent Biopharma Inc stock is traded at $22.42, with a volume of 588.62K.
It is up +3.70% in the last 24 hours and up +9.69% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$21.62
Open:
$22.03
24h Volume:
588.62K
Relative Volume:
1.36
Market Cap:
$925.53M
Revenue:
-
Net Income/Loss:
$-136.98M
P/E Ratio:
-5.5771
EPS:
-4.02
Net Cash Flow:
$-126.63M
1W Performance:
+5.01%
1M Performance:
+9.69%
6M Performance:
+32.27%
1Y Performance:
-16.65%
1-Day Range:
$21.71
$23.40
1-Week Range:
$20.00
$23.40
52-Week Range:
$15.47
$28.12
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
22.42 | 892.50M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 6.8%Still a Buy? - MarketBeat
Growth Prospects for the EGFR-NSCLC Market Analyzed - Intellectia AI
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 5.6%Here's Why - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Trading Systems Reacting to (AVBP) Volatility - Stock Traders Daily
Targets Report: Whats the profit margin of ArriVent BioPharma IncJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
$207B Market Shift: The Race for Fast Track Approval in Oncology - The Malaysian Reserve
$207B Market Shift: The Race for Fast Track Approval in Oncology (2026-02-05) - Seeking Alpha
Aug Catalysts: Is ASTC a play on infrastructure spending2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Breakouts Watch: Can ArriVent BioPharma Inc maintain sales growthJuly 2025 Retail & Fast Gain Stock Trading Tips - baoquankhu1.vn
Big Money Moves Out of ArriVent BioPharma - TipRanks
Is ArriVent BioPharma Inc. stock vulnerable to regulatory risks2025 Top Decliners & Long-Term Safe Return Strategies - mfd.ru
What’s next for ArriVent BioPharma Inc. stockTrade Ideas & Consistent Growth Equity Picks - mfd.ru
How Arrivent Biopharma Inc. (AVBP) Affects Rotational Strategy Timing - Stock Traders Daily
Death Cross: Does First Commonwealth Financial Corporation offer margin of safetyEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Pullback Watch: Will FOXF benefit from green energy policiesEarnings Beat & Scalable Portfolio Growth Ideas - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5.8%Here's What Happened - MarketBeat
JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
Notable Thursday Option Activity: AVBP, GRAL, APPN - Nasdaq
Fed Watch: What’s next for ArriVent BioPharma Inc. stock2025 Geopolitical Influence & AI Forecasted Stock Moves - baoquankhu1.vn
ArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLC - MSN
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 8.2%What's Next? - MarketBeat
Can ArriVent BioPharma Inc. stock resist market sell offs - bollywoodhelpline.com
Rate Cut: Should I trade or invest in Materialise NV Depositary ReceiptOil Prices & Stock Portfolio Risk Control - baoquankhu1.vn
Technical Analysis: Is ArriVent BioPharma Inc subject to activist investor interest2025 Earnings Impact & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Entry Recap: Will SHIP outperform tech stocksQuarterly Portfolio Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
(AVBP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 7.2%Should You Buy? - MarketBeat
Aug Drivers: Should you avoid Zura Bio Limited stock right nowEarnings Summary Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
Aug Volume: Can ArriVent BioPharma Inc. stock attract ESG capital inflowsJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - Улправда
Can ArriVent BioPharma Inc. stock attract ESG capital inflowsJuly 2025 Rallies & Entry Point Strategy Guides - Улправда
Will ArriVent BioPharma Inc. stock see insider buyingQuarterly Market Review & Fast Moving Stock Trade Plans - Улправда
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock By Investing.com - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 7.4%Here's What Happened - MarketBeat
Responsive Playbooks and the AVBP Inflection - Stock Traders Daily
ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring A 99.97% Potential Upside - DirectorsTalk Interviews
Firmonertinib Trial Aims to Crack a Long-Standing Lung Cancer Treatment Gap - MyChesCo
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha
(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2%What's Next? - MarketBeat
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug - Investing.com Australia
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating - Investing.com
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study - TipRanks
ArriVent BioPharma Begins Phase 3 Trial of Firmonertinib in Lung Cancer - marketscreener.com
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):